ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,308.15
1.17%
US Tech 100
18,138.80
1.69%
다우존스 지수
39,908.00
0.88%
Bitcoin
66,140.88
-0.18%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Coya Therapeutics Inc (COYA)

  7. Coya Therapeutics Inc (COYA) 뉴스

COYA

Coya Therapeutics (COYA)

Coya Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:COYA
일자시간출처헤드라인심볼기업
2024/05/1005:26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COYACoya Therapeutics Inc
2024/05/1005:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COYACoya Therapeutics Inc
2024/05/1005:10Business WireCoya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial ResultsNASDAQ:COYACoya Therapeutics Inc
2024/05/0906:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COYACoya Therapeutics Inc
2024/04/2621:15Business WireCoya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumNASDAQ:COYACoya Therapeutics Inc
2024/04/2221:15Business WireCoya Therapeutics to Participate in the Mizuho Neuroscience SummitNASDAQ:COYACoya Therapeutics Inc
2024/04/1821:15Business WireCoya Therapeutics to Participate in the 3rd Annual ALS Drug Development SummitNASDAQ:COYACoya Therapeutics Inc
2024/04/0821:15Business WireCoya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumNASDAQ:COYACoya Therapeutics Inc
2024/03/1921:15Business WireCoya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial ResultsNASDAQ:COYACoya Therapeutics Inc
2024/03/1222:00Business WireCoya Therapeutics to Participate in BTIG Fireside DiscussionNASDAQ:COYACoya Therapeutics Inc
2024/03/1221:00Business WireCoya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology ConferenceNASDAQ:COYACoya Therapeutics Inc
2024/03/0622:15Business WireCoya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 ConferenceNASDAQ:COYACoya Therapeutics Inc
2024/03/0610:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
2024/02/2922:15Business WireCoya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 ConferenceNASDAQ:COYACoya Therapeutics Inc
2024/02/2222:15Business WireCoya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology ConferenceNASDAQ:COYACoya Therapeutics Inc
2024/02/2122:15Business WireCoya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”NASDAQ:COYACoya Therapeutics Inc
2024/02/1322:15Business WireCoya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory DiseasesNASDAQ:COYACoya Therapeutics Inc
2024/02/0310:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
2024/02/0310:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
2024/01/2922:15Business WireCoya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology ConferenceNASDAQ:COYACoya Therapeutics Inc
2024/01/2008:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
2024/01/2008:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
2024/01/2008:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
2024/01/1922:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COYACoya Therapeutics Inc
2024/01/1822:15Business WireCoya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call SeriesNASDAQ:COYACoya Therapeutics Inc
2024/01/1706:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:COYACoya Therapeutics Inc
2024/01/1622:15Business WireCoya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral SclerosisNASDAQ:COYACoya Therapeutics Inc
2024/01/1618:06PR Newswire (US)DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed FinancingNASDAQ:COYACoya Therapeutics Inc
2024/01/1617:59PR Newswire (US)DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed FinancingNASDAQ:COYACoya Therapeutics Inc
2024/01/0522:00Business WireCoya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)NASDAQ:COYACoya Therapeutics Inc
 검색 관련기사 보기:NASDAQ:COYA

최근 히스토리

NASDAQ
MSFT
Microsoft
NASDAQ
GOOGL
Alphabet
NYSE
AXP
American Express
SPI
SP500
S&P 500
PM
XAUUSD
Gold vs US Dollar
NYSE
BAC
Bank of America
CCOM
SILVER
SILVER
NYSE
MCD
McDonalds
USOTC
DTEGY
Deutsche Telekom (QX)
CCOM
US100
US Tech 100
USI
USTECH100
US Tech 100
FX
USDGBP
US Dollar vs Sterling
NYSE
MRK
Merck
NYSE
CVX
Chevron
CCOM
US30
US 30
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유